Loading
Nanoparticle-based Drug Delivery / Nanoplatforms for Cancer Theranostics · Journal article
Molecules · September 8, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review synthesizing the rationale and preclinical potential for aptamer- and gold nanoparticle-based targeted therapy in colorectal cancer. The authors propose these systems as drug delivery platforms to address limitations of current chemotherapy but explicitly acknowledge that preclinical studies are ongoing and further validation of biodistribution and safety is warranted. No clinical trial data, efficacy endpoints, or comparative evidence are presented.
Narrative review article. Colorectal cancer patients globally; focus on low-resource settings where death rates are expected to increase..
Colorectal cancer accounts for approximately 10% of all cancer cases globally, with estimated 1.9 million cases and 930,000 deaths in 2022. Current chemotherapy is limited by poor bioavailability, multidrug resistance, and adverse bystander effects. Authors project that aptamers combined with AuNPs may improve delivery of chemotherapeutics to CRC cells, but acknowledge paucity of targeted CRC treatment information and need for further validation.
Authors explicitly state biodistribution and safety profiles remain unvalidated. Current chemotherapy is limited by poor bioavailability, multidrug resistance, and adverse bystander effects.
This review presents a conceptual framework for targeted CRC therapy but does not provide evidence to guide clinical practice. Clinicians should recognize this as early-stage mechanistic exploration; aptamer- and gold nanoparticle-based systems remain investigational with no established clinical role.
This is a narrative review exploring preclinical aptamer and gold nanoparticle strategies for colorectal cancer, presenting mechanistic concepts and projected benefits without clinical trial data or empirical validation.
As stated by the source record.
Quoted from the source exactly as published.
This review presents a conceptual framework for targeted CRC therapy but does not provide evidence to guide clinical practice. Clinicians should recognize this as early-stage mechanistic exploration; aptamer- and gold nanoparticle-based systems remain investigational with no established clinical role.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Colorectal cancer (CRC) is the second leading cause of cancer-associated mortality and accounts for ~10% of all cancer cases. Global CRC cases were estimated at 1.9 million and 930,000 deaths in 2022. Despite improved access to CRC screening and treatment, death rates are expected to drastically increase in low-resource areas, highlighting an urgent need for innovative CRC treatment interventions. Current chemotherapy presents challenges, such as poor bioavailability, multidrug resistance, and adverse bystander effects. Therefore, it is imperative to develop new and CRC-specific therapeutic strategies. Targeted therapy has significantly improved drug delivery and efficacy in the treatment of various diseases, including cancer. Although several preclinical studies are currently ongoing in cancer therapy, there is a paucity of information about targeted CRC treatment. Hence, this review highlights the promising role of aptamer- and gold nanoparticles (AuNPs)-based systems for targeted CRC treatment. This strategy leverages the unique properties of aptamers and AuNPs as drug carriers, targeting and therapeutic agents. Overall, aptamers in combination with AuNPs are projected to improve the delivery of chemotherapeutics to CRC cells. However, further studies are warranted to validate the biodistribution and safety profile of aptamer- and AuNPs-based systems as potential tools for CRC treatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.